Lord, Abbett & Co. LLC Alector, Inc. Transaction History

Lord, Abbett & Co. LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$10.54 - $24.96 $1.82 Million - $4.3 Million	-172,255 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$21.87 - $33.11 $2.01 Million - $3.04 Million	-91,814 Reduced 34.77%	172,255 $4.21 Million
Q1 2020 May 14, 2020	BUY	$16.25 - $35.28 $161,508 - $350,647	9,939 Added 3.91%	264,069 $6.37 Million
Q4 2019 Feb 14, 2020	SELL	$14.17 - $20.3 $947,434 - $1.36 Million	-66,862 Reduced 20.83%	254,130 $4.38 Million
Q3 2019 Nov 14, 2019	SELL	$14.42 - $22.2 $3.57 Million - $5.5 Million	-247,872 Reduced 43.57%	320,992 $4.63 Million
Q2 2019 Aug 14, 2019	BUY	$16.26 - $26.42 $1.22 Million - $1.97 Million	74,738 Added 15.13%	568,864 $10.8 Million
Q1 2019 May 15, 2019	BUY	$15.97 - $22.5 $7.89 Million - $11.1 Million	494,126 New	494,126 $9.25 Million

167

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $149M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.